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Abstract Increased elastinolytic activity has been correlated 
with the degree of lung damage occurring in a variety of lung 
diseases including cystic fibrosis; serine proteinase inhibitors are 
currently on trial for the treatment of some lung disorders. 
ttowever, human lung lavage cells also secrete metallo-dependent 
elastases. Here we show, for the first time, that whilst these are 
readily inhibited by EDTA, inhibition of serine elastases using 
serpins (serine proteinase inhibitors) is not always possible. This 
may reflect inactivation of serpins by uninhibited metalloprotein- 
ases and oxidants in a low protein milieu. Thus, the therapeutic 
inhibition of excessive elastinolytic activity may require a 
combination of inhibitors to work efficiently. 
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~. Introduction 
An increase in the proteolytic activity of respiratory tract 
~ecretions, in particular an excess of elastinolytic activity, has 
been implicated in the pathology of a number of pulmonary 
,onditions including cystic fibrosis and acute lung injury, as 
well as in diseases of tobacco smokers such as bronchitis and 
~mphysema [1-5]. 
Elastinolytic enzymes are released by the polymorphonuc- 
ear neutrophil, which produces at least two serine-dependent 
~lastases, neutrophil elastase (EC 3.4.21.37) and proteinase 3
EC 3.4.21.76), and the alveolar macrophage which can 
,ynthesize cysteinyl- and metalloenzymes with elastinolytic ac- 
iv ity (reviewed in [6]). The first elastinolytic enzyme to be 
dentified was neutrophil elastase, an enzyme with a broad 
,pectrum of pro-inflammatory activity; in addition to its elas- 
inolytic properties, it can act as a secretagogue, stimulate 
GM-CSF release from alveolar macrophages and act as a 
aeutrophil chemoattractant by activating C5a and stimulating 
IL-8 production by epithelial cells. Recently, attention has 
bcused on the matrix metalloproteinases (MMPs). Alveolar 
nacrophages constitutively produce MMPs-2, 3, 9, 10 and 12 
md, thus, can degrade a variety of connective tissue compo- 
aents, including elastin. 
The relative importance of the extracellular release of these 
iifferent classes of enzyme into the airspaces is unclear since 
':hey have differing activities on a molar basis [6] and because 
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epithelial secretions contain inhibitors for all three classes of 
enzyme. Furthermore, the enzymes of one class may inactivate 
the inhibitors and activate the proenzymes of another class; 
either action could potentially amplify the elastinolytic burden 
of the lung. For example, neutrophil elastase can both activate 
metalloelastase (MMP-12; EC 3.4.24) and cleave its inhibi- 
tors; conversely, MMP-12 can inactivate at least one serine 
proteinase inhibitor (or serpin), ct-l-proteinase inhibitor [7]. 
As alveolar macrophages and neutrophils are often found in 
close proximity in the respiratory tract, particularly in patho- 
logical states, for example cystic fibrosis, such interactions 
may amplify the total elastase burden, so increasing the sever- 
ity of tissue damage. 
To evaluate the elastinolytic potential of proteases released 
by mixed populations of bronchoalveolar lavage cells (BAL 
cells), we have quantified the relative and total activities of 
serine elastases and matrix metalloproteinases released by 
BAL cells from patients. In addition, in order to establish 
the overall effect of inhibition of one class of enzyme (as 
might occur during the therapeutic use of ct-1-proteinase in- 
hibitor), we have observed their interactions in the presence of 
the serine- and metalloproteinase inhibitors, t~-l-proteinase 
inhibitor and EDTA, and the highly specific inhibitor of neu- 
trophil elastase, N~-(1-adamantanesulphonyl)-N~-(4-carboxy - 
benzoyl)-L-lysyl-L-alanyl-L-valinal (Ro 31-3537, also known 
as 'Compound 3' [8,9]). 
2. Materials and methods 
2.1. Collection of bronchoalveolar lavage from patients 
Bronchoalveolar lavage was collected from 14 sequential patients 
(25 66 years, median 54 years) undergoing routine fibreoptic broncho- 
scopy with lavage as part of their diagnostic work-up; most were 
undergoing investigation for suspected bronchial carcinoma. Seven 
were current smokers and seven ex- or non-smokers. Ex-smokers 
had not smoked for at least 2 years prior to the bronchoscopy. 
Bronchoalveolar lavage, performed as previously described [4], was 
used to collect material from a region of the lung which was radio- 
graphically normal and normal on visual inspection. The recovered 
fluid and cells were processed as described previously [4]. No sample 
had evidence of haemorrhage or severe inflammation (taken as 1 x 10 ~ 
neutrophils/ml). 
2.2. Bronchoalveolar lavage cell culture 
Mixed BAL cells were plated at a concentration f 106 cells/ml in 
Dulbecco's modified Eagle's medium (DMEM) or low protein hybri- 
doma medium (LPHM; Gibco, UK) in 24 well plates. After 1 h, the 
conditioned medium and any non-adherent cells were removed and 
cells and medium separated by centrifugation [10]. The acellular con- 
ditioned media were stored at -20°C until analysis. The adherent cells 
were cultured for a further 3 h in the equivalent volume of fresh 
medium, then the conditioned media harvested and stored as before. 
2.3. Elastinolytic activity in conditioned media; effect of native and 
synthetic inhibitors 
Samples of conditioned media were preincubated for 30 min at 
37°C with an equal volume of 0.1 mol/l Tris-HCl, pH 7.0 (to measure 
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total elastase activity) or buffer containing elastase inhibitors: ct-1- 
proteinase inhibitor (192.5 nmol/1; Sigma, UK), EDTA (100 pmol/l; 
Sigma, UK) or Ro 31-3537 (1 mmol/1), in the final concentrations 
shown in parentheses. Uninhibited elastase activity was then measured 
by quantifying the release of soluble lastin peptides from an insoluble 
[aH]elastin substrate (Elastin Products, MI, USA) as previously de- 
scribed [4]. Human neutrophil elastase (Elastin Products) of known 
activity [11], made up in DMEM or LPHM as appropriate, was used 
as a standard. Sample, inhibitor and reagent blanks in DMEM and 
LPHM were assayed as described above. 
2.4. Effect of incubation time on the inhibitory capacity of 
tx-l-proteinase inhibitor against elastinolytic activity 
Samples of DMEM conditioned by exposure to cells (n = 6 subjects) 
were preincubated with ¢t-1-proteinase inhibitor for 30 min at 37°C as 
described above. They were then incubated with [3H]elastin for 24 h 
as described previously [4] or for 4 h only, after which uninhibited 
elastase activity was measured as described above. 
2.5. Investigation of elastase: ct-l-proteinase inhibitor mixtures for 
modified tx-l-proteinase inhibitor 
Samples of o~-l-proteinase inhibitor (70/.tg) which had been prein- 
cubated for 30 min at 37°C with neutrophil elastase (0.025-25 pg in 
DMEM) or conditioned DMEM, were concentrated bycentrifugation 
at 5000xg for 1.5 h at 4°C through Centricon filters with a nominal 
molecular mass cut-off of 10 kDa (Amicon, UK). Concentrates were 
Western blotted [10] and stained for ~t-l-proteinase inhibitor with a 
specific polyclonal antibody (DAKO, UK). 
2.6. Statistics 
The Wilcoxon rank sum test for unpaired ata or the Wilcoxon 
signed rank test for paired data was used as appropriate, taking the 
level of significance as P < 0.05 in a two-tailed test. 
3. Results 
3.1. Bronchoalveolar lavage data 
Fluid recoveries and BAL cell numbers and profiles are 
shown in Table 1. There were no significant differences in 
differential cell counts (mainly alveolar macrophages) between 
the BAL cells cultured in DMEM and those cultured in 
LPHM. Approximately 50% of the cells adhered after 1 h in 
culture irrespective of the medium used. 
3.2. Initial elastinolytic activities in conditioned media in the 
absence of  inhibitors 
Elastinolytic activity in media conditioned by the mixed 
BAL cell population was significantly greater than that in 
media conditioned by adherent cells alone, even when allow- 
ance was made for cell number (not shown); there was no 
significant difference in elastinolytic activity between the two 
types of culture medium (Table 1). 
. I  1 [ ,  T " ° "  "° [] .... 
, ,1= = ....... I)I,, ° 
Fig. 1. Inhibition of extracellular elastinolytic activity from cultured 
BAL cells. Inhibition of extracellular elastinolytic activity from total 
BAL cell populations (panel i) and adherent BAL cells alone (panel 
ii). Activities in the presence of inhibitors are expressed as percen- 
tages of the initial values (in the absence of any added inhibitor). 
Median values with the interquartile ranges, a < initial elastinolytic 
activity, b > initial elastinolytic activity, c > LPHM, d < media con- 
ditioned by total cell population; P< 0.05. 
3.3. Elastinolytic activities in conditioned media in the presence 
of inhibitors 
Neither c~-l-proteinase inhibitor nor Ro 31-3537 inhibited 
elastinolytic activity released in to DMEM, although both 
consistently inhibited activity released into LPHM (Fig. 1). 
Choice of medium had no effect on the inhibitory capacity 
of EDTA, which consistently inhibited 30% of the elastinolyt- 
ic activity in media conditioned by total BAL cell populations 
and approximately 60% of that in media conditioned by ad- 
herent BAL cells (Fig. 1). 
3.4. Effect of incubation time on inhibition of  elastinolytic 
activity in DMEM by c~-l-proteinase inhibitor 
After a 4 h incubation with [ZH]elastin, c~-l-proteinase in- 
hibitor reduced the initial elastinolytic activity of paired media 
from three subjects and enhanced that from the other three 
pairs (Fig. 2). When the time of incubation with elastin was 
increased to 24 h, a-l-proteinase inhibitor enhance the elasti- 
nolytic activity of all the conditioned media tested (Fig. 2). 
3.5. Western blotting 
Western blotting showed evidence of ct-l-proteinase inhibi- 
tor complex formation in the presence of both conditioned 
media and pure neutrophil elastase; this could be increased 
using increasing amounts of neutrophil elastase relative to ct- 
1-proteinase inhibitor (Fig. 3). However, there was no evi- 
dence of tx-l-proteinase inhibitor fragmentation by condi- 
tioned media or neutrophil elastase at the concentrations 
used in the experiments described above (Fig. 3). 
Table 1 
Fluid and cell recovery from bronchoalveolar l vage; profile of cells cultured in LPHM and DMEM and elastinolytic activity released by total 
and adherent BAL cells 
LPHM (n = 6) DMEM (n = 8) 
Fluid (% instilled) 
BAL cells (X 106) 
Alveolar macrophages (%) 
Neutrophils (%) 
Lymphocytes (%) 
Media conditioned by total cell population 
Elastinolytic activity (ng/ml medium/h) 
Media conditioned by adherent cells 
Elastinolytic activity (ng/ml medium/h) 
53 (27-71) 39 
28 .1  (16.8-38.7) 48.6 
89 (78-97) 88 
3 (0-15) 4 
5 (1-19) 7 
25 (7-83) 38 
7 (2-30)* 15 
The elastinolytic activities of conditioned media are expressed in neutrophil elastase quivalents. 
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F g. 2. Effect of incubation time on inhibition of elastinolytic activ- 
ilJ in conditioned media by a-l-proteinase inhibitor. Each symbol 
rvpresents DMEM conditioned by cells from the same subject. The 
il itial elastinolytic activity (in the absence of inhibitors) varied con- 
siJerably between subjects (see Table 1). This initial activity is ex- 
p essed as 1 for all subjects in order to demonstrate whether incuba- 
tim with a-l-proteinase inhibitor decreased or increased the activity 
a:ld for clarity of illustration. In five out of six paired samples, in- 
c:easing the time of incubation with e~-l-proteinase inhibitor in- 
c eased the measurable elastinolytic activity. 
4 Discussion 
Since unrestrained elastinolytic activity from inflammatory 
c~,lls is believed to contribute to the pathogenesis of a variety 
of lung diseases, there is considerable interest in using elastase 
i~.hibitors therapeutically. Hence, it is necessary to character- 
i~e the enzymes which contribute to the elastinolytic burden in 
tLe human lung in order to use effective inhibitors; cultured 
I~AL cells provide us with a means of doing this relatively 
n on-invasively. In the current study, we detected elastinolytic 
a.:tivity in media conditioned by patients' BAL cells (Table 1), 
cmfirming that these cells possess and release elastinolytic 
elzymes. Interestingly, when DMEM was used as a culture 
~tedium, we were able to inhibit only metallo-dependent las- 
t nolytic activity; furthermore, lastinolytic activity was higher 
rtther than lower when serine-elastase inhibitors were present 
(Zig. 1). In contrast, if LPHM was used, serine-dependent 
e azymes could be inhibited as expected. 
A possible explanation for these observations i that oxi- 
cants produced by the cells in culture remain reactive in 
I ~MEM, but not in LPHM and, thus, can inactivate a- l -pro- 
t ~inase inhibitor when it is subsequently added to conditioned 
I)MEM, but not conditioned LPHM. The latter is a supple- 
r-~ented medium relatively rich in proteins, which are known 
t ) scavenge cell-derived oxidants. In contrast, DMEM is not 
s applemented; in the absence of complex molecules, cell-de- 
ved oxidants might interact with amino acids in DMEM, but 
i ~main able to undergo subsequent reactions with added pro- 
t.ins, in this case a-l-proteinase inhibitor, by which they 
v'ould finally be consumed. (For example, specific amino acids 
lave previously been shown to potentiate the toxicity of oxi- 
ciants [12].) c~-l-Proteinase inhibitor is particularly susceptible 
t)  inactivation by oxidation, since it has a methionine residue 
~, t its active site [13,14]. In contrast, neutrophil elastase, which 
tas no methionine at its active site, is relatively less affected 
I-,y oxidants [15]. Since pro-matrix metalloproteinases can be 
activated both by serine proteinases such as neutrophil elas- 
tase and by cell-derived oxidants [16], such metalloproteinases 
could inactivate a-l-proteinase inhibitor [17] and enable con- 
tinued neutrophil elastase activity. Thus, overall, elastinolysis 
would be amplified. We found no evidence of c~-l-proteinase 
inhibitor degradation and only minimal complex formation of 
c~-l-proteinase inhibitor with neutrophil elastase in condi- 
tioned medium (Fig. 3), suggesting that the c~-l-proteinase 
inhibitor was inactivated either by enzymatic nicking of the 
reactive site loop or by oxidation of the reactive site methio- 
nine, neither of which would be detected by Western blotting. 
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Fig. 3. Immunoblot showing the effect of pure neutrophil elastase 
and conditioned media on the format of a-l-proteinase inhibitor. 
Panel i: Lane A, pure a-l-proteinase inhibitor; lane B, pure neutro- 
phil elastase; lane C, ~-l-proteinase inhibitor following preincuba- 
tion with neutrophil elastase in the molar ratio 400:1; lanes D and 
F, samples of conditioned DMEM; lanes E and G, exogenous c~-l- 
proteinase inhibitor following preincubation with the same condi- 
tioned media. The molecular weight of ~-l-proteinase inhibitor, 54 
kDa, was unaffected by any treatment. Panel ii: Lanes A and G, 
pure c~-l-proteinase inhibitor; lane B, pure neutrophil elastase; the 
remaining lanes contain c~-l-proteinase inhibitor following preincu- 
bation with neutrophil elastase in the molar ratios: lane C, 400:1; 
lane D, 40:1; lane E, 4:1; lane F, 0.4:1. Native a-l-proteinase inhi- 
bitor had a molecular weight of 55 kDa. Inhibitor:enzyme com- 
plexes (72 kDa) were formed at low molar ratios (lanes D, E and 
F). At ratios unlikely to occur in vivo (lanes E and F), partially de- 
graded c~-l-proteinase inhibitor (49 and 62 kDa) was observed. 
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by contamination of the tx-l-proteinase inhibitor by neutro- 
phil elastase. 
At the concentrations u ed in this study, EDTA does not 
inhibit neutrophil elastase (data not shown). Approximately 
30% and 60% of the elastinolytic activity released by total and 
adherent BAL cell populations respectively is metallo-depend- 
ent. This activity is likely to be from alveolar macrophages, 
which predominate in the adherent cell population, although 
there were a few adherent neutrophils which may have re- 
leased some of the EDTA-susceptible lastases. The enzymes 
most likely to have contributed this activity are MMP-9 (ge- 
latinase B; EC 3.4.24.35), which is released by alveolar macro- 
phages and neutrophils, and MMP-12, a metalloelastase from 
alveolar macrophages which may be implicated in the patho- 
genesis of emphysema [6]; these two enzymes make up 50% of 
the matrix metalloproteinase elastase activity released by al- 
veolar macrophages [6]. The EDTA-resistant elastinolytic ac- 
tivity released into the conditioned media was largely serine- 
dependent, since in LPHM it was inhibited by ct-l-proteinase 
inhibitor and Ro 31-3537. Cysteine-dependent lastases (EC 
3.4.22) require an acid milieu and thus would not be active 
under the assay conditions used, nor following extracellular 
release in vivo. Normally the synthesis and release of serine- 
dependent elastases and matrix metalloproteinases is strictly 
regulated; where there is an imbalance in the normal BAL cell 
profile, so that activated neutrophils and alveolar macro- 
phages are in close proximity, for example, in smokers and 
patients with cystic fibrosis, the co-release of proteolytic en- 
zymes may amplify the overall elastinolytic burden by the 
processes described above. 
In summary, mixed populations of BAL cells contain, and 
may release, a variety of elastinolytic enzymes, the diversity of 
which may prolong increased activity, for example by the 
proteolytic activation of pro-enzymes. The presence of metal- 
loenzymes was a consistent feature; matrix metalloproteinases 
contribute about 30% of the activity released by the total cell 
population, largely from the alveolar macrophage. Impor- 
tantly, the elastinolytic enzymes released by mixed popula- 
tions of BAL cells cannot be controlled by a single inhibitor. 
This has implications for the therapeutic use of serine-protein- 
ase inhibitors such as ct-l-proteinase inhibitor which may be 
inactivated by non-serine proteinases. Finally, we have dem- 
onstrated the importance of a high protein environment to 
'buffer' ct-l-proteinase inhibitor against inactivation by metal- 
loproteinases and oxidants; this may be of particular impor- 
tance in smokers, who often have less protein in their epithe- 
lial lining fluid than non-smokers [4]. 
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